Abstracts tagged "small molecules and tofacitinib"

Abstract Number: 586 • 2018 ACR/ARHP Annual Meeting
Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World DATA from the ST. Gallen and-Aarau RA-Cohort
Ruediger Mueller¹, Caroline Hasler², Florian Popp³, Frederik Mattow⁴, Mirsada Durmisi⁵, Andrea Rubbert-Roth⁶, Alexander Souza⁷, Nicole Graf⁸, Hendrik Schulze-Koops⁹, Paul Hasler¹⁰ and Johannes von Kempis¹¹, ¹Division of Rheumatology, Kantonsspital St Gallen, St. Gallen, Switzerland, ²on of Rheumatology, Kantonsspital Aarau, Aarau, Switzerland, ³Division of Rheumatology, Immunology and Rehabilitation, Kantonsspital St. Gallen, St. Gallen, Switzerland, ⁴Kantonsspital St. Gallen, St. Gallen, Switzerland, ⁵Division of Rheumatology, Kantonsspital Aarau, Aarau, Switzerland, ⁶Kantonsspital St Gallen, St Gallen, Switzerland, ⁷Iterata AG, Gränichen, Switzerland, ⁸Graf Biostatistics, Winterthur, Switzerland, ⁹Ludwig-Maximilians-University, Munich, Germany, Munich, Germany, ¹⁰Kantonsspital Aarau AG, Aarau, Switzerland, ¹¹Division of Rheumatology and Immunology, Kantonsspital St. Gallen, St. Gallen, Switzerland
Background/Purpose: Tofacitinib is an oral JAK inhibitor approved for the treatment of RA. Efficacy and safety of tofacitinib have been shown in several randomized clinical…
Abstract Number: 1495 • 2018 ACR/ARHP Annual Meeting
Baseline Characteristics of Methotrexate Inadequate Responder Patients with RA Who Achieved Low Disease Activity with Tofacitinib Monotherapy
Jeffrey Kaine¹, Alan J. Kivitz², Eduardo Mysler³, Noriko Iikuni⁴, Haiyun Fan⁵, Annette Diehl⁵, Jerome Paulissen⁶ and Christopher W Murray⁵, ¹Sarasota Arthritis Research Center, Sarasota, FL, ²Altoona Center for Clinical Research, Duncansville, PA, ³Organización Médica de Investigación, Buenos Aires, Argentina, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, Collegeville, PA, ⁶Syneos Health, Raleigh, NC
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. ORAL Strategy (NCT02187055) was a Phase 3b/4, 1-year, double-blind, triple-dummy, active comparator-controlled…
Abstract Number: 2595 • 2016 ACR/ARHP Annual Meeting
Real World Results from a Post-Approval Safety Surveillance of Tofacitinib (Xeljanz): Over 3 Year Results from an Ongoing US-Based Rheumatoid Arthritis Registry
Arthur F. Kavanaugh¹, Jamie Geier², Clifton Bingham III³, Connie Chen², George W. Reed^4,5, Katherine C. Saunders⁴, Yan Chen⁶, Andrew Koenig⁶, Laura Cappelli⁷, Jeffrey D. Greenberg^4,8 and Joel M. Kremer⁹, ¹University of California, San Diego School of Medicine, LaJolla, CA, ²Pfizer, Inc., New York, NY, ³Johns Hopkins University, Baltimore, MD, ⁴Corrona, LLC, Southborough, MA, ⁵University of Massachusetts Medical School, Worcester, MA, ⁶Pfizer, Inc., Collegeville, PA, ⁷Medicine/Rheumatology, Johns Hopkins University, Baltimore, MD, ⁸NYU School of Medicine, New York, NY, ⁹Albany Medical College and the Center for Rheumatology, Albany, NY
Background/Purpose: An interim analysis of a prospective observational 3+ year study, embedded within the US Corrona Rheumatoid Arthritis (RA) registry (14 years and ongoing), was…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].